ArticleThe international journal of neuropsychopharmacology2026
Exploring the association between sweet liking and treatment response to naltrexone in patients with alcohol use disorder.
Article in The international journal of neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundResponse to naltrexone varies among individuals with alcohol use disorder (AUD). Studies in Western populations have linked the sweet-liking (SL) phenotype, reflecting an individual's hedonic response to sweet taste, to improved outcomes with naltrexone. However, cultural and ethnic variations in SL raise questions about the generalizability of this association. This exploratory investigation examined the relationship between SL phenotype and naltrexone treatment outcomes in Taiwanese patients with AUD.
methodsPatients with DSM-5-defined severe AUD who had completed alcohol withdrawal were enrolled in an 8-week open-label naltrexone trial. Participants completed a sweet taste test and were categorized into SL or sweet-disliking (SDL) groups. Outcomes included alcohol consumption (drinking days per week, heavy drinking days per week, drinks per drinking day, abstinent days), alcohol craving, and depression and anxiety severity. Generalized estimating equations were used to assess the effects of time, group, and their interaction.
resultsNinety-one patients were enrolled (SL: n = 44; SDL: n = 47). Baseline characteristics were comparable between groups, except for smoking-related variables. After adjusting for smoking, both groups showed improvements in alcohol use and psychological measures over time. A significant group-by-time interaction was found for drinks per drinking day, with the SL group showing more favorable outcomes than the SDL group (P = .03).
conclusionsThis is the first exploratory investigation in Asians to assess SL phenotype in relation to naltrexone response in AUD patients. The SL phenotype was associated with reduced alcohol consumption over 8 weeks of naltrexone treatment, supporting SL phenotype as a potential biomarker for personalized AUD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.